Pionyr and Abcam extend partnership to evaluate TREM2-expressing cells in cancer patients

SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, England: SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, England, June 22, 2021 /PRNewswire/ -- Today Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that increase the body's anti-tumor immunity and Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life science reagents and tools,...

Click to view original post